GLMD vs. PBLA, DRMA, GRI, CMRA, INM, QLGN, LSDI, NBSE, BPTH, and CMND
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Panbela Therapeutics (PBLA), Dermata Therapeutics (DRMA), GRI Bio (GRI), Comera Life Sciences (CMRA), InMed Pharmaceuticals (INM), Qualigen Therapeutics (QLGN), Lucy Scientific Discovery (LSDI), NeuBase Therapeutics (NBSE), Bio-Path (BPTH), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical preparations" industry.
Panbela Therapeutics (NASDAQ:PBLA) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Panbela Therapeutics presently has a consensus target price of $500.00, indicating a potential upside of 121,851.22%. Given Galmed Pharmaceuticals' higher possible upside, equities research analysts clearly believe Panbela Therapeutics is more favorable than Galmed Pharmaceuticals.
In the previous week, Panbela Therapeutics and Panbela Therapeutics both had 2 articles in the media. Galmed Pharmaceuticals' average media sentiment score of 0.00 beat Panbela Therapeutics' score of -0.50 indicating that Panbela Therapeutics is being referred to more favorably in the media.
4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Galmed Pharmaceuticals received 424 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Panbela Therapeutics an outperform vote while only 65.77% of users gave Galmed Pharmaceuticals an outperform vote.
Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
Panbela Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
Panbela Therapeutics' return on equity of -53.29% beat Galmed Pharmaceuticals' return on equity.
Summary
Galmed Pharmaceuticals beats Panbela Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
